Category:

Release – Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TNXP

June 30, 2025 7:00am EDT

Download as PDF

CHATHAM, N.J., June 30, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the open of U.S. equity markets today, June 30, 2025, as part of the 2025 Russell indexes reconstitution.

The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

“This milestone reflects the significant growth and development Tonix has experienced over the past year,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “We look forward to the increased visibility and awareness that inclusion in the Russell Indexes brings as we advance toward the potential FDA approval and planned launch of TNX-102 SL for the management of fibromyalgia later this year.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider.

For more information on the Russell 3000® Index and Russell 2000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

Tonix Pharmaceuticals Holding Corp.*
Tonix is a fully-integrated biotech company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years. TNX-4200 is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Peter Vozzo
ICR Healthcare
peter.vozzo@icrhealthcare.com
(443) 213-0505

Media Contact

Ray Jordan
Putnam Insights
ray@putnaminsights.com
(949) 245-5432

Indication and Usage

Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.

Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.

Important Safety Information

Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:

  • discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw or stomach
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded

Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.

Do not use Zembrace or Tosymra if you have:

  • history of heart problems
  • narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
  • uncontrolled high blood pressure
  • hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
  • had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation
  • severe liver problems
  • taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.
  • are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
  • an allergy to sumatriptan or any of the components of Zembrace or Tosymra

Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.

Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.

Zembrace and Tosymra may cause serious side effects including:

  • changes in color or sensation in your fingers and toes
  • sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever
  • cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet
  • increased blood pressure including a sudden severe increase even if you have no history of high blood pressure
  • medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
  • serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
  • hives (itchy bumps); swelling of your tongue, mouth, or throat
  • seizures even in people who have never had seizures before

The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).

Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.

This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.

You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Primary Logo

Source: Tonix Pharmaceuticals Holding Corp.

Released June 30, 2025

Aurania Resources (AUIAF) – Promising New Data Highlights the Potential for a Significant Copper Discovery

Posted on by slightbourne@noblecapitalmarkets.com


Monday, June 30, 2025

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Application of two-dimensional inversion technology. Aurania Resources announced that six highly conductive anomalies have been revealed at the company’s Awacha porphyry copper target based on reprocessed data from a 2021 mobile magnetotellurics (MobileMT) survey using the latest two-dimensional (2D) inversion technology. Compared to the previously employed 1D algorithm, the 2.5D code accounts for the actual topography of the area, resulting in more accurate mapping of subsurface conductivity.

Six promising anomalies at Awacha. New inversion data has confirmed the presence of six high-conductivity anomalies that begin 250 meters from the surface and exhibit deep roots. The anomalies are of significant interest because zones of elevated conductivity often correlate with porphyry copper deposits due to the presence of conductive sulphide minerals and porphyry-related alteration.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Home Depot’s SRS Distribution to Acquire GMS Inc. in $5.5 Billion Deal

Posted on by slightbourne@noblecapitalmarkets.com

GMS Inc. (NYSE: GMS), a major distributor of specialty building products across North America, has entered into a definitive agreement to be acquired by SRS Distribution, a subsidiary of The Home Depot. The transaction, valued at approximately $5.5 billion including net debt, marks a significant step in expanding The Home Depot’s distribution capabilities through its fast-growing specialty trade arm.

Under the agreement, SRS will launch a tender offer to purchase all outstanding shares of GMS for $110.00 per share in cash—representing a 36% premium over GMS’s closing stock price on June 18, 2025. The acquisition is expected to close by the end of The Home Depot’s current fiscal year, pending regulatory approvals and a majority tender of GMS shares.

Founded in 1971, GMS has built a strong presence in the building materials sector, offering a wide range of products including wallboard, ceilings, steel framing, and complementary items through its network of over 320 distribution centers and nearly 100 tool sales and rental locations. The company’s consistent growth has been guided by a strategy focused on expanding its core product sales, growing complementary offerings, extending its platform, and driving productivity and profitability.

Following the acquisition, GMS will continue to operate under its current leadership. CEO John C. Turner Jr. and the existing senior management team will remain at the helm, overseeing day-to-day operations as part of the SRS organization.

The merger aims to significantly enhance service and fulfillment options for both residential and commercial contractors. By combining GMS’s industry leadership and product breadth with SRS’s expansive footprint—already spanning more than 800 locations—the unified business will operate over 1,200 branches and manage a delivery fleet of more than 8,000 trucks.

SRS Distribution CEO Dan Tinker emphasized the value of the partnership, stating that the integration of GMS into the SRS platform will result in a powerful distribution network capable of servicing tens of thousands of job sites daily.

This acquisition also builds on The Home Depot’s strategic use of SRS as a platform for growth. Since acquiring SRS, Home Depot has leveraged synergies including shared service offerings, cross-selling opportunities, and integration of trade credit solutions, contributing to its broader strategy of supporting professional contractors more comprehensively.

Once finalized, the deal is expected to increase The Home Depot’s capacity to serve the growing demands of the pro customer segment, strengthening its position across both residential and commercial construction markets.

AbbVie to Acquire Capstan Therapeutics in $2.1B Deal, Advancing Novel Autoimmune Treatment Technologies

Posted on by slightbourne@noblecapitalmarkets.com

AbbVie has announced a definitive agreement to acquire Capstan Therapeutics, a clinical-stage biotechnology company pioneering targeted in vivo cell engineering, in a deal valued at up to $2.1 billion. The acquisition includes Capstan’s lead asset, CPTX2309—an investigational therapy targeting B cell-mediated autoimmune diseases—as well as the company’s proprietary targeted lipid nanoparticle (tLNP) platform for RNA delivery.

This strategic move signals AbbVie’s growing commitment to reshaping the treatment landscape for autoimmune diseases. While AbbVie has long been a major player in immunology with blockbuster therapies like Humira and Rinvoq, the addition of Capstan’s in vivo CAR-T capabilities positions the company at the frontier of a new therapeutic modality.

CPTX2309 is an mRNA-based therapy that delivers an anti-CD19 chimeric antigen receptor (CAR) directly into CD8-expressing cytotoxic T cells via Capstan’s tLNP system. Unlike traditional ex vivo CAR-T therapies, which require harvesting and engineering a patient’s cells outside the body before reinfusion, CPTX2309 enables this transformation to happen in vivo. This significantly simplifies the treatment process by eliminating the need for lymphodepletion or complex manufacturing steps—making it potentially more scalable and accessible.

Targeting CD19, a well-validated marker expressed on B cells, CPTX2309 aims to deplete the autoreactive B cells responsible for driving autoimmune diseases such as lupus or multiple sclerosis. The goal is to eliminate the pathogenic immune cells and repopulate the system with naïve, healthy B cells—effectively resetting the immune system and halting disease progression.

AbbVie is not only acquiring a promising clinical candidate but also a platform technology with broad applications. Capstan’s proprietary CellSeeker™ tLNP platform can be adapted to deliver a variety of RNA payloads to specific cell types in vivo, opening possibilities far beyond autoimmune conditions. This could have future implications for oncology, infectious diseases, and more.

As part of the agreement, AbbVie will make a cash payment of up to $2.1 billion at closing, subject to customary regulatory and legal conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Act.

This acquisition adds to AbbVie’s expanding immunology pipeline and enhances its positioning in next-generation therapeutic development. By integrating Capstan’s cutting-edge technology, AbbVie aims to develop new approaches that go beyond treating symptoms and instead target the root causes of autoimmune disorders.

The transaction is expected to close later this year. Capstan was advised by Centerview Partners LLC as financial advisor and Cooley LLP as legal counsel. AbbVie did not disclose its legal or advisory team.

This deal reflects a growing industry trend of major pharmaceutical companies investing heavily in advanced RNA delivery platforms and in vivo cell therapies—technologies seen as essential to the next wave of personalized medicine. With this acquisition, AbbVie reaffirms its commitment to driving innovation that transforms the standard of care for patients worldwide.

Take a moment to take a look at more emerging growth biotechnology companies by taking a look at Noble Capital Markets’ analyst Robert LeBoyer’s coverage list.

U.S. and China Cement Trade Agreement, Signaling Easing of Rare Earth and Tech Restrictions

Posted on by slightbourne@noblecapitalmarkets.com

The United States and China have confirmed the finalization of a new trade framework that aims to ease ongoing tensions over rare earth exports and high-tech restrictions, offering a cautious step forward in the complex trade relationship between the two global superpowers.

According to China’s Ministry of Commerce, the agreement outlines reciprocal actions: China will review and approve export applications for goods subject to control rules, while the United States will begin lifting a range of restrictive measures previously targeting Beijing. While the announcement did not specify which exports or restrictions will be affected, the move signals a broader effort to stabilize bilateral trade ties.

This development follows remarks from U.S. officials confirming that a framework agreement had recently been signed. The new accord builds on groundwork laid earlier this year during high-level talks in Geneva, and more recently in London, where Treasury Secretary Scott Bessent and Chinese Vice Premier He Lifeng led discussions that helped shape the final structure of the deal.

The London meetings reaffirmed both sides’ interest in implementing the Geneva consensus, which had paused a significant portion of bilateral tariffs for 90 days and introduced initial efforts to de-escalate commercial pressures. That earlier agreement had come after months of strained communications, with both countries accusing one another of delaying policy rollbacks.

Though the agreement has been received as a sign of progress, analysts have highlighted the lack of detailed commitments on critical components such as rare earth elements. These materials, essential to the production of semiconductors, electric vehicles, and defense technology, remain a key point of leverage in ongoing U.S.-China negotiations. Both countries have historically viewed rare earths as strategic assets, and any long-term easing of restrictions is expected to be handled with caution.

In addition to export concerns, tensions had also mounted over U.S. limitations on Chinese access to advanced technologies and student visa policies. The latest agreement is expected to reduce some of those barriers, although specifics have yet to be disclosed.

Observers note that while this step could bring a temporary reprieve to certain industries—particularly tech manufacturing and defense-related supply chains—significant challenges remain. The nature of the agreement, without clearly defined measures, may limit its immediate impact and leaves room for further diplomatic friction.

Financial markets reacted modestly, with shares in key industrial and tech sectors showing slight gains. Stakeholders across both countries are now expected to monitor implementation efforts closely to determine how the agreement translates into policy and trade flows on the ground.

Although the finalized trade framework provides an opening for improved relations, the success of the deal will depend on continued engagement, transparency, and measurable outcomes as the global economic landscape continues to evolve.

Release – New Inversion Data Reveals Six Anomalies at Aurania’s Awacha Target

Posted on by aweinsoff@channelchek.com

Research News and Market Data on AUIAF

June 27, 2025 7:00 AM EDT | Source: Aurania Resources Ltd.

Toronto, Ontario–(Newsfile Corp. – June 27, 2025) – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (“Aurania” or the “Company”) reports that reprocessing Mobile MagnetoTellurics (MobileMT) data from the Company’s Awacha porphyry copper target in Ecuador using the latest 2D inversion technology has revealed six highly conductive anomalies.

In 2021, Aurania contracted Expert Geophysics Surveys Inc. to conduct a MobileMT airborne survey over the Awacha porphyry copper target area. At that time, Electromagnetic (EM) data inversion was performed using a one-dimensional (1D) algorithm. In recent years, EM inversion technology has significantly improved, particularly for areas with rugged terrain. As a result, Aurania recommissioned Expert Geophysics Surveys Inc. to reprocess the existing MobileMT data using the latest 2D inversion technology. The 2.5D code applied is more objective and comprehensive than the previous 1D technology, as it takes into account the actual topography of the area being investigated, yielding robust lateral and vertical resolution, resulting in more accurate mapping of the subsurface conductivity.

The new inversion data has confirmed the presence of six high-conductivity anomalies as shown in Figure 1. These conductive anomalies typically begin 250 metres from the surface and exhibit deep roots as seen in Figure 2. These anomalies are significant since zones of elevated conductivity often correlate with porphyry copper deposits due to the presence of electrically conductive sulphide minerals (pyrite, chalcopyrite and bornite) and porphyry-related alteration (phyllic and argillic zones).

The new MobileMT 2.5D inversion results will be integrated with data and field observations from the Anaconda mapping program that was completed at Awacha in 2024. Aurania has engaged porphyry copper expert, Dr. Steve Garwin, a Senior Technical Advisor (see press release dated April 19, 2022), to review the Anaconda mapping data to identify the most promising porphyry targets at the Awacha area. Dr. Garwin’s report and recommendations are expected in the coming weeks.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/2477/257054_10219f4304bee802_001.jpg

Figure 1: MobileMT depth slice at 700 m above sea level showing six anomalies at the Awacha target area (red colour is high conductivity and blue colour is high resistivity).

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/2477/257054_10219f4304bee802_001full.jpg

Cannot view this image? Visit: https://images.newsfilecorp.com/files/2477/257054_10219f4304bee802_002.jpg

Figure 2: East-west cross section of the MobileMT 2.5D inversion at the Awacha target area (dashed line in Figure 1, looking north).

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/2477/257054_10219f4304bee802_002full.jpg

Qualified Persons:
The geological information contained in this news release has been verified and approved by Aurania’s VP Exploration, Mr. Jean-Paul Pallier, MSc. Mr. Pallier is a designated EurGeol by the European Federation of Geologists and a Qualified Person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators.

About Aurania
Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America. Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedarplus.ca, as well as on Facebook at https://www.facebook.com/auranialtd/, X (formerly Twitter) at https://x.com/AuraniaLtd , and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir
VP Corporate Development & Investor Relations
Aurania Resources Ltd.
(416) 367-3200
carolyn.muir@aurania.com

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements
This news release contains forward-looking information as such term is defined in applicable securities laws, which relate to future events or future performance and reflect management’s current expectations and assumptions. The forward-looking information includes Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the tonnage and grade of mineralization which has the potential for economic extraction and processing, the merits and effectiveness of known process and recovery methods, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations, the commencement of any drill program and estimates of market conditions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to Aurania, including the assumption that, there will be no material adverse change in metal prices, all necessary consents, licenses, permits and approvals will be obtained, including various local government licenses and the market. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. Risk factors that could cause actual results to differ materially from the results expressed or implied by the forward-looking information include, among other things: failure to identify mineral resources; failure to convert estimated mineral resources to reserves; the inability to complete a feasibility study which recommends a production decision; the preliminary nature of metallurgical test results; the inability to recover and process mineralization using known mining methods; the presence of deleterious mineralization or the inability to process mineralization in an environmentally acceptable manner; commodity prices, supply chain disruptions, restrictions on labour and workplace attendance and local and international travel; a failure to obtain or delays in obtaining the required regulatory licenses, permits, approvals and consents; an inability to access financing as needed; a general economic downturn, a volatile stock price, labour strikes, political unrest, changes in the mining regulatory regime governing Aurania; a failure to comply with environmental regulations; a weakening of market and industry reliance on precious metals and base metals; and those risks set out in the Company’s public documents filed on SEDAR+. Aurania cautions the reader that the above list of risk factors is not exhaustive. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

info

SOURCE: Aurania Resources Ltd.

V2X (VVX) – An $118 Million Contract

Posted on by cpatches


Friday, June 27, 2025

V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Support Services. According to the daily Department of Defense contract announcements, V2X subsidiary Vectrus Systems has been awarded an $118 million cost-plus-fixed-fee undefinitized contract for base support services in support of the Iraq F-16 program. This is another in a long line of recent wins for V2X, demonstrating the V2X value proposition and confirming the significant traction on near-term Foreign Military and International opportunities previously highlighted by management.

Details. The contract provides for base operating support, base life support, and security services. Work will be performed at Martyr BG Ali Flaih Air Base, Iraq, and is expected to be completed by Nov. 30, 2026. This contract involves Foreign Military Sales (FMS) to Iraq. This contract was a sole source acquisition. FMS funds in the amount of $57.8 million are being obligated at the time of award.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Steelcase (SCS) – Post Call Commentary

Posted on by cpatches


Friday, June 27, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Mixed Environment. Steelcase continues to face a mixed environment, both on a vertical basis and a geographical basis. The key large corporate customer cohort is doing well, driven by a number of factors such as return to office, but education and government have been hit by funding uncertainties. Germany and France remain sluggish in the key small-to-mid-sized business, but India and China are doing better.

International Actions. Steelcase is taking steps to implement additional cost reduction efforts in Europe, given the weak macroeconomic factors and lower demand in France and Germany. A goal of these actions is to get the International segment back to profitability.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Bit Digital (BTBT) – A Flurry of News

Posted on by cpatches


Friday, June 27, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

News. Bit Digital released a flurry of news over the past two days, including a strategic shift in its business strategy, the potential IPO of its WhiteFiber subsidiary, and a $150 million equity offering. Needless to say, a lot to digest. If completed, the announced shifts would result in a significant change to Bit Digital.

Ethereum Focus. Operationally, Bit Digital will exit the bitcoin mining business and transition to become a pure-play Ethereum staking and treasury company. Given the economics of bitcoin mining versus Ethereum staking, we see the rationale in the move. The Company has commenced a strategic alternatives process for the Bitcoin mining operations.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

AZZ (AZZ) – Quarterly Cash Dividend Increased by 17.6%, 1Q FY2026 Financial Results to be Released on July 9

Posted on by cpatches


Friday, June 27, 2025

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Increase in the quarterly cash dividend. AZZ announced a 17.6% increase in the quarterly cash dividend to $0.20 per share, or $0.80 on an annualized basis, from $0.17 per share, or $0.68 on an annualized basis. The dividend is payable on July 31 to shareholders of record as of the close of business on July 10. In our view, the dividend increase reflects management’s confidence in the company’s near- and long-term outlook.

First Quarter FY 2026 financial results. AZZ will release its first quarter financial results after the market close on Wednesday, July 9. Management will host an investor conference call and webcast on Thursday, July 10, at 11:00 am ET. We look forward to an update regarding the company’s new aluminum coil coating facility in Washington, Missouri, that is ramping up production, along with a review of market fundamentals and the company’s capital allocation priorities.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

XOMA Acquires Turnstone in $0.34 Per Share Deal with Future Payouts

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– XOMA will acquire Turnstone for $0.34 per share plus a CVR.
– 25.2% of shareholders have agreed to the deal.
– The acquisition expands XOMA’s biotech royalty portfolio.

In a notable development in the biotech investment landscape, XOMA Royalty Corporation has entered into a definitive agreement to acquire Turnstone Biologics Corp. in a cash and contingent value right (CVR) transaction. The acquisition underscores XOMA’s continued push to expand its royalty and milestone-driven portfolio by targeting biotech firms with high-risk, high-reward therapeutic assets.

Under the terms of the deal announced June 27, XOMA Royalty will pay $0.34 per share in cash to Turnstone shareholders, along with a non-transferable CVR tied to future clinical or commercial milestones. The transaction was unanimously approved by Turnstone’s board following a comprehensive strategic review, indicating strong alignment between both companies on the benefits of the proposed merger.

The transaction will be executed through a tender offer, which XOMA is expected to launch by July 11, 2025. To move forward, the offer requires acceptance by holders representing at least a majority of Turnstone’s outstanding shares, along with other standard closing conditions including a minimum cash balance at the time of closing.

Significantly, shareholders representing roughly 25.2% of Turnstone’s stock have already agreed to support the deal and tender their shares, increasing the likelihood of a successful outcome. If the tender offer is completed as planned, remaining shares not tendered—excluding any subject to appraisal rights—will be converted into the same cash and CVR terms. The full acquisition is anticipated to close by August 2025.

The CVR element of the deal provides Turnstone shareholders with potential upside depending on the progress of its pipeline, which historically has focused on Selected Tumor-Infiltrating Lymphocyte (Selected TIL) therapy for the treatment of solid tumors. While the company has faced challenges in recent quarters, its research has positioned it within a promising niche of the immuno-oncology space.

Turnstone has partnered with Leerink Partners as financial advisor and Cooley LLP for legal counsel during the transaction process. On the acquiring side, XOMA is represented by legal firm Gibson, Dunn & Crutcher LLP.

This acquisition adds another layer to XOMA’s unique business model, which focuses on purchasing future economic rights—royalties and milestone payments—from pre-commercial and commercial biotech programs. These rights are typically tied to therapies developed and licensed out by smaller biotech companies to larger pharmaceutical firms. In return, the selling firms receive non-dilutive capital they can reinvest into pipeline development or general operations.

By bringing Turnstone into its fold, XOMA potentially gains exposure to novel cancer therapies while giving Turnstone a viable financial exit at a time when biotech funding remains tight. The CVR component allows existing shareholders to benefit from any future success tied to Turnstone’s core scientific work, creating a hybrid payout structure aligned with both short-term liquidity and long-term optionality.

The transaction reflects a growing trend in biotech M&A, where royalty aggregators like XOMA leverage strategic acquisitions to build long-term value while offering capital relief to development-stage firms.

As of now, both companies remain focused on a smooth closing process, with investors watching closely to see how Turnstone’s science and XOMA’s model will align in the quarters ahead.

CoreWeave Pursues $4B Deal to Power AI Ambitions with Core Scientific

Posted on by slightbourne@noblecapitalmarkets.com

CoreWeave, the rapidly rising AI cloud infrastructure provider, is once again making headlines — this time for reigniting acquisition talks with bitcoin mining giant Core Scientific. According to a report by The Wall Street Journal, the companies are in advanced discussions that could lead to a deal in the coming weeks, pending negotiations.

The move marks a notable turn in a high-stakes courtship that began last year, when CoreWeave made an unsolicited offer to acquire Core Scientific for $1.02 billion. That bid, valued at $5.75 per share, was promptly rejected by Core Scientific for undervaluing the company. Fast-forward a year, and Core Scientific’s market value has climbed to nearly $4 billion, with shares rising roughly 8% following the renewed acquisition chatter.

CoreWeave’s interest in the company is strategic. As AI workloads continue to demand massive computational power and access to stable energy supplies, former crypto mining operations like Core Scientific have become increasingly attractive targets. With expansive infrastructure already in place, these facilities offer AI players a fast track to scaling data centers without starting from scratch.

CoreWeave and Core Scientific already have history. Following the failed acquisition attempt in 2024, the companies entered a multi-decade partnership involving 12-year infrastructure contracts. Among them was a landmark deal in which Core Scientific committed to providing CoreWeave with 200 megawatts of power capacity to support its high-performance computing operations. That agreement alone signaled a convergence between the worlds of cryptocurrency and artificial intelligence — both of which depend on energy-intensive server farms.

The potential acquisition now appears to be a natural next step in that partnership. By bringing Core Scientific under its umbrella, CoreWeave would not only secure long-term access to critical power infrastructure but also strengthen its foothold in the competitive AI cloud race — a space dominated by the likes of Amazon, Google, and Microsoft.

While the exact financial terms of the revived offer have not been disclosed, market analysts suggest any deal would likely exceed the previous $1 billion bid, given Core Scientific’s increased valuation and rising relevance in the post-crypto AI landscape.

Still, a finalized agreement is not guaranteed. Regulatory scrutiny, shifting market conditions, or resistance from shareholders could delay or derail the talks. Neither Core Scientific nor CoreWeave has publicly commented on the latest developments.

The acquisition would mark another significant move in a broader trend: tech and AI companies consolidating energy assets and computing infrastructure once built for cryptocurrency mining. As AI continues to evolve and expand, the race to control the digital and physical backbones of computation is heating up — and CoreWeave is positioning itself at the center.

Mortgage Rates Fall Below 6.8%, Offering Little Spark for Home Sales

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Mortgage rates fell to 6.77%, the lowest since May, as Treasury yields dipped.
– High rates and home prices continue to constrain homebuyer activity.
– Forecasters expect only modest rate relief through the end of the year.

Mortgage rates have inched lower for a fourth straight week, offering a glimmer of relief for homebuyers, but not enough to spark a major rebound in the housing market. The average 30-year fixed mortgage rate dropped to 6.77% this week, its lowest level since May, down slightly from 6.81% last week, according to data from Freddie Mac. The average rate for a 15-year mortgage also dipped to 5.89% from 5.96%.

This modest decline comes as geopolitical tensions ease and Treasury yields soften. A recent ceasefire between Iran and Israel helped calm global markets, while dovish comments from Federal Reserve officials increased expectations that rate cuts could come as early as July. These factors contributed to a dip in the 10-year Treasury yield, which mortgage rates tend to closely follow.

Though the Federal Reserve has not moved to lower interest rates yet, speculation around future cuts is already influencing mortgage rate behavior. Fed Chair Jerome Powell reiterated during recent congressional testimony that while rate cuts are not imminent, the central bank remains open to adjusting policy if inflation continues to cool or if economic conditions shift.

Despite the recent rate movement, mortgage rates are still hovering near the upper end of a narrow range. Since mid-April, rates have fluctuated within a tight 15-basis-point band, limiting their ability to meaningfully impact housing affordability.

High borrowing costs, coupled with persistently high home prices, have continued to dampen housing activity. While pending home sales rose by 1.8% in May from the previous month, and 1.1% year-over-year, the overall housing market remains subdued. New home sales, in contrast, fell sharply last month, plunging 14% — the steepest monthly drop in three years, highlighting buyer hesitation in the current rate environment.

Mortgage applications for new purchases were essentially flat last week, according to the Mortgage Bankers Association, while refinancing activity saw a modest 3% increase. The latter suggests that some homeowners are finding incentive in even small rate drops to restructure their existing loans, though the overall refinancing market remains a fraction of what it was during the ultra-low rate environment of the pandemic.

Looking ahead, economists expect only gradual improvement. The Mortgage Bankers Association projects rates to close out the year around 6.7%, while Fannie Mae anticipates a slightly more optimistic 6.5%. Either way, most forecasts suggest a slow decline rather than a swift return to significantly lower levels.

For prospective buyers, this means affordability may improve modestly, but major relief remains unlikely in the short term. With inflation, Federal Reserve policy, and global uncertainty still in play, the mortgage market is expected to remain cautious.